Background
Capon and Eshhar were rival inventors competing in an interference proceeding before the Patent and Trademark Office Board of Patent Appeals and Interferences over patents covering chimeric genes — artificial DNA constructs that combine portions of different naturally occurring genes. These chimeric genes encoded chimeric proteins designed to be expressed on the surface of immune system cells such as T-cells, enabling those cells to target specific disease sites, including tumors. The technology represented an early form of what would later become known as chimeric antigen receptor T-cell (CAR-T) therapy — a revolutionary cancer treatment approach.
Both inventors’ claimed chimeric genes combined antibody-binding DNA segments with T-cell receptor DNA segments, using known molecular biology techniques. The component DNA segments — the antibody portion and the lymphocyte receptor portion — were individually well-characterized and their nucleotide sequences were publicly known in the scientific literature at the time the applications were filed. The Board invalidated all claims from both parties on written description grounds, reasoning that the specifications failed to adequately disclose the complete nucleotide sequences of the claimed chimeric genes. Both parties appealed to the Federal Circuit.
The Court’s Holding
The Federal Circuit reversed, holding that the Board had applied an overly rigid per se rule that was inconsistent with the flexible, context-sensitive written description requirement of 35 U.S.C. § 112. Writing for the court, Judge Newman held that a biotechnology patent specification need not recite the complete nucleotide sequence of claimed DNA when the relevant sequences are already known in the field.
The court explained that the written description requirement measures whether the specification demonstrates that the inventors were in possession of the claimed invention at the time of filing — it does not require inventors to repeat information that is already part of the scientific literature and well within the knowledge of skilled practitioners in the field. When the component parts of a claimed invention are individually known and their sequences are documented in the prior art, a specification that clearly identifies those known components and explains how to combine them using standard techniques adequately demonstrates possession of the invention.
The court emphasized that written description analysis must be applied in the context of the particular invention and the state of knowledge in the relevant field at the time of filing. For biotechnology inventions involving combinations of known genetic elements, categorical rules requiring full sequence recitation would impose an unnecessary and counterproductive burden on inventors whose innovations lie in the creative combination and application of known elements, not in the discovery of new sequences.
Key Takeaways
- The written description requirement does not impose a per se rule requiring recitation of complete nucleotide sequences in biotechnology patent specifications when the relevant sequences are already known in the scientific field at the time of filing.
- Written description is satisfied when the specification demonstrates inventors were in possession of the claimed invention — which can be accomplished by clearly identifying known components and describing how to combine them, without redundantly reproducing publicly available sequence information.
- Written description analysis must be context-sensitive, taking into account the state of knowledge in the relevant field: what counts as adequate disclosure for a claim to a truly novel sequence differs from what is needed for a claim to a novel combination of known sequences.
- This case is significant for biotechnology patent drafting: specifications should clearly identify the known components being combined and reference the publicly available sequences, while describing the inventive combination and its functional characteristics.
- The decision is historically significant as it addressed early CAR-T technology — the chimeric gene approach described in the patents presaged engineered immune cell therapies that would later become major cancer treatments.
Why It Matters
Capon v. Eshhar is an important precedent for biotechnology patent law, addressing the tension between the written description requirement and the pace of discovery in modern molecular biology. By rejecting a rigid per se rule requiring full sequence recitation, the Federal Circuit acknowledged that innovation in biotechnology often builds on known genetic building blocks, combining them in new ways to create new functions. Requiring inventors to reproduce publicly available sequence data in every patent specification would impose a paperwork burden without serving the informational purposes of the patent disclosure requirement.
The case has practical importance for the growing field of engineered cell therapy and gene therapy. As CAR-T cell therapies and related technologies have emerged as transformative cancer treatments, the patent law principles governing disclosure of chimeric gene inventions have become increasingly important. Patent prosecutors in the biotechnology and pharmaceutical industries routinely rely on Capon v. Eshhar when defending written description adequacy of gene and protein patent claims that combine known genetic elements into novel functional constructs.